In this edition, Top Teamproposed five topics to a pharmaceutical industry professional who briefly talks about them. Our guest this edition is Fabio Ferreira Médici, Business Development Manager at Roche. “The fractionated medicine may be useful except for some pharmaceuticals applications and certain therapeutic classes”, says Médici. Click on it and check it out:

Top Team: The pharmaceutical industry dynamism.

Fabio Ferreira Médici: Undoubtdfully dynamism is the key to stand out in market either concerning the company or the executive. Any implemented action will be known by the market within few hours which will cause a fast feedback from competition. As in the classic statement: “it is increasingly present in our daily life.”

Top Team: Fractionated medicines.

Fabio Ferreira Médici: I agree with FEBRAFARMA opinion. During the medicine register process ANVISA has tried to make posologies, therapeuctic recommendations and commercial presentations compatible in order to reduce the amount of non standard prescriptions and worldwide medical consensus. However, it is quite usual to trade medicine in packages containing different amounts with corresponding prices and efficient treatments.

There are technical objections such as: stability and microbiological contamination besides regulatory laws that limitate the donation of fractionated medicines at the points of sale added to the medical ones that establish a limited amount of medicine crucial to cure or revert the symptoms presented by a certain patient. We cannot forget to mention that most diseases are chronic and require continuous medical treatment, leading to sanitary risk when fractionated medicine is recommended once it does not guarentee the patient’s commitment to the treatment. The fractionated medicine may be useful only for certain medicines and therapeutic classes so that the number of medicines available and likely to be fractionated is reduced.

Next page >>